Recursion Total Operating Expenses vs Operating Income Analysis

RXRX Stock  USD 5.84  0.32  5.80%   
Recursion Pharmaceuticals financial indicator trend analysis is much more than just breaking down Recursion Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Recursion Pharmaceuticals is a good investment. Please check the relationship between Recursion Pharmaceuticals Total Operating Expenses and its Operating Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Total Operating Expenses vs Operating Income

Total Operating Expenses vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Recursion Pharmaceuticals Total Operating Expenses account and Operating Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Recursion Pharmaceuticals' Total Operating Expenses and Operating Income is -0.95. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Operating Income in the same time period over historical financial statements of Recursion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Recursion Pharmaceuticals' Total Operating Expenses and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Recursion Pharmaceuticals are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Total Operating Expenses i.e., Recursion Pharmaceuticals' Total Operating Expenses and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.95
Relationship DirectionNegative 
Relationship StrengthSignificant

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Operating Income

Operating Income is the amount of profit realized from Recursion Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Recursion Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Recursion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Recursion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.At this time, Recursion Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 5.83 in 2025, whereas Tax Provision is likely to drop (1.2 M) in 2025.
 2022 2023 2024 2025 (projected)
Depreciation And Amortization11.8M24.4M36.5M38.3M
Interest Income6.3M18.3M15.8M16.5M

Recursion Pharmaceuticals fundamental ratios Correlations

0.950.990.990.980.920.880.99-0.92-0.970.940.870.950.980.120.160.860.930.86-0.290.96-0.920.960.980.30.98
0.950.940.980.910.910.760.98-0.84-0.960.970.790.980.91-0.110.340.710.930.89-0.190.98-0.870.970.930.380.91
0.990.940.980.960.910.860.98-0.89-0.980.940.840.960.960.020.180.830.930.88-0.250.95-0.940.980.970.320.96
0.990.980.980.960.950.871.0-0.93-0.990.940.880.960.970.070.160.840.910.87-0.290.99-0.930.970.980.310.97
0.980.910.960.960.890.950.97-0.91-0.950.890.870.91.00.250.020.890.880.83-0.480.94-0.940.930.990.11.0
0.920.910.910.950.890.860.94-0.95-0.950.810.930.840.890.11-0.040.850.750.81-0.280.97-0.940.910.930.30.89
0.880.760.860.870.950.860.86-0.9-0.870.710.880.740.940.45-0.280.930.690.71-0.640.86-0.930.810.94-0.10.95
0.990.980.981.00.970.940.86-0.9-0.990.950.860.970.970.040.190.810.920.88-0.310.99-0.920.980.980.280.97
-0.92-0.84-0.89-0.93-0.91-0.95-0.9-0.90.9-0.77-0.97-0.79-0.92-0.340.14-0.95-0.73-0.730.28-0.910.89-0.84-0.9-0.29-0.91
-0.97-0.96-0.98-0.99-0.95-0.95-0.87-0.990.9-0.92-0.87-0.94-0.95-0.01-0.12-0.83-0.88-0.910.3-0.980.97-0.99-0.98-0.29-0.96
0.940.970.940.940.890.810.710.95-0.77-0.920.711.00.9-0.120.460.660.990.87-0.160.91-0.790.950.90.380.9
0.870.790.840.880.870.930.880.86-0.97-0.870.710.730.870.36-0.210.960.660.77-0.260.88-0.870.790.860.30.86
0.950.980.960.960.90.840.740.97-0.79-0.941.00.730.91-0.140.420.680.980.89-0.180.93-0.840.970.920.380.91
0.980.910.960.971.00.890.940.97-0.92-0.950.90.870.910.260.040.90.890.82-0.440.94-0.930.920.990.141.0
0.12-0.110.020.070.250.110.450.04-0.34-0.01-0.120.36-0.140.26-0.720.52-0.11-0.17-0.540.04-0.12-0.120.16-0.460.24
0.160.340.180.160.02-0.04-0.280.190.14-0.120.46-0.210.420.04-0.72-0.310.490.290.490.130.10.250.050.530.04
0.860.710.830.840.890.850.930.81-0.95-0.830.660.960.680.90.52-0.310.650.69-0.390.81-0.860.740.860.140.88
0.930.930.930.910.880.750.690.92-0.73-0.880.990.660.980.89-0.110.490.650.85-0.160.87-0.760.920.880.370.89
0.860.890.880.870.830.810.710.88-0.73-0.910.870.770.890.82-0.170.290.690.85-0.150.87-0.840.910.860.40.83
-0.29-0.19-0.25-0.29-0.48-0.28-0.64-0.310.280.3-0.16-0.26-0.18-0.44-0.540.49-0.39-0.16-0.15-0.320.45-0.26-0.460.82-0.47
0.960.980.950.990.940.970.860.99-0.91-0.980.910.880.930.940.040.130.810.870.87-0.32-0.930.970.970.280.94
-0.92-0.87-0.94-0.93-0.94-0.94-0.93-0.920.890.97-0.79-0.87-0.84-0.93-0.120.1-0.86-0.76-0.840.45-0.93-0.93-0.96-0.11-0.94
0.960.970.980.970.930.910.810.98-0.84-0.990.950.790.970.92-0.120.250.740.920.91-0.260.97-0.930.960.310.93
0.980.930.970.980.990.930.940.98-0.9-0.980.90.860.920.990.160.050.860.880.86-0.460.97-0.960.960.130.99
0.30.380.320.310.10.3-0.10.28-0.29-0.290.380.30.380.14-0.460.530.140.370.40.820.28-0.110.310.130.11
0.980.910.960.971.00.890.950.97-0.91-0.960.90.860.911.00.240.040.880.890.83-0.470.94-0.940.930.990.11
Click cells to compare fundamentals

Recursion Pharmaceuticals Account Relationship Matchups

Recursion Pharmaceuticals fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets298.6M610.3M701.3M653.7M1.4B1.5B
Short Long Term Debt Total15.7M11.5M51.0M50.7M108.5M113.9M
Other Current Liab19.7M32.3M27.0M46.6M81.9M86.0M
Total Current Liabilities23.1M46.7M100.3M93.2M187.5M196.8M
Total Stockholder Equity(206.3M)542.9M485.8M463.4M1.0B1.1B
Property Plant And Equipment Net26.0M64.7M121.4M120.2M233.2M244.9M
Net Debt(246.5M)(273.6M)(498.9M)(340.9M)(485.9M)(510.2M)
Retained Earnings(213.6M)(400.1M)(639.6M)(967.6M)(1.4B)(1.4B)
Accounts Payable1.1M2.8M4.6M4.0M21.6M22.7M
Cash262.1M285.1M549.9M391.6M594.4M394.7M
Non Current Assets Total29.1M75.6M131.5M215.6M734.3M771.0M
Non Currrent Assets Other650K8.7M7.9M6.9M14.5M15.2M
Other Assets650K8.7M7.9M1.01.151.09
Long Term Debt11.4M633K536K1.1M19.0M20.0M
Cash And Short Term Investments262.1M516.6M549.9M391.6M594.4M437.1M
Net Receivables156K9.1M2.8M3.1M49.2M51.6M
Liabilities And Stockholders Equity298.6M610.3M701.3M653.7M1.4B1.5B
Non Current Liabilities Total481.8M20.7M115.2M97.1M226.3M154.7M
Capital Lease Obligations3.2M10.8M50.4M49.5M81.0M85.1M
Inventory5.0M1.6M1.3M(3.1M)(2.8M)(2.6M)
Other Current Assets2.2M9.1M17.1M43.5M70.8M74.3M
Other Stockholder Equity(441M)943.1M1.1B1.4B2.5B2.6B
Total Liab504.9M67.4M215.5M190.3M413.8M296.5M
Net Invested Capital(193.8M)543.7M486.4M464.6M1.1B1.1B
Property Plant And Equipment Gross26.0M83.5M121.4M165.0M295.9M310.7M
Short Long Term Debt1.1M90K97K41K8.4M8.8M
Total Current Assets269.5M534.7M569.8M438.1M714.3M477.2M
Net Working Capital246.4M488.1M469.5M345.0M526.8M393.3M
Short Term Debt2.0M1.5M12.0M6.2M22.2M23.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.